New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Discover what makes Paris's biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Sanofi is harnessing the power of pop music to boost awareness of the experience of living with Type 1 diabetes. The French drugmaker has sponsored the formation of a new girl group, dubbed 1Type ...

Sanofi, Formation Bio and OpenAI have jointly designed an AI-powered tool that will be rolled out in the former's phase 3 multiple sclerosis trials. There’s a new Muse in town.

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...